1. Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy

   • Hongjie Huo
   • Yu Feng
   • Qiong Tang

   Original Article Open access 04 January 2024 Pages: 397 - 410

   

2. Ruthenium–dihydroartemisinin complex: a promising new compound for colon cancer prevention via G1 cell cycle arrest, apoptotic induction, and adaptive immune regulation

   • Chong-Zhi Wang
   • Chunping Wan
   • Chun-Su Yuan

   Original Article 09 January 2024 Pages: 411 - 425

   

3. Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells

   • Thamir M. Mahgoub
   • Emmet J. Jordan
   • Denis M. Collins

   Original Article Open access 16 January 2024 Pages: 427 - 437

   

4. Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants

   • Romain Sechaud
   • Helen Gu
   • Hans D. Menssen

   Original Article 25 January 2024 Pages: 439 - 453

   

5. Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells

   • Alexandr N. Chernov
   • Alexandr V. Kim
   • Olga V. Shamova

   Original Article 27 January 2024 Pages: 455 - 469

   

6. Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study

   • Bin Fan
   • Ghassan K. Abou-Alfa
   • Hua Yang

   Original Article Open access 27 January 2024 Pages: 471 - 479

   

7. The landscape of very important pharmacogenes variants and potential clinical relevance in the Chinese Jingpo population: a comparative study with worldwide populations

   • Xiaoya Ma
   • Yujie Li
   • Tianbo Jin

   Original Article 01 February 2024 Pages: 481 - 496

   

8. Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitors

   • Kadriye Bir Yücel
   • Uguray Aydos
   • Ozan Yazıcı

   Original Article 04 March 2024 Pages: 497 - 507

   

9. Pharmacology and pharmacokinetics of tazemetostat

   • Marco Orleni
   • Jan H. Beumer

   Brief Report 23 March 2024 Pages: 509 - 517

   

10. Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report

    • M. Berge
    • J. S. Giraud
    • B. Blanchet

    Letter to the Editor 03 November 2023 Pages: 519 - 521

    

11. Retraction Note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment

    • Mototsugu Oya
    • Shuichi Kaneko
    • Yutaka Okayama

    Retraction Note Open access 16 September 2023 Pages: 523 - 523